Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy
- PDF / 193,662 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 19 Downloads / 189 Views
CORRECTION
Open Access
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWnPlasma) trial Timothy Devos1,2*†, Tatjana Geukens1,2†, Alexander Schauwvlieghe3†, Kevin K. Ariën4, Cyril Barbezange5, Myriam Cleeren1, Veerle Compernolle6, Nicolas Dauby7, Daniël Desmecht8, David Grimaldi9, Bart N. Lambrecht3, Anne Luyten10, Piet Maes11, Michel Moutschen8, Marta Romano5, Lucie Seyler12, Michel Toungouz Nevessignsky13, Katleen Vandenberghe10, Johan van Griensven4, Geert Verbeke14, Erika Vlieghe15, Jean Cyr Yombi16, Laurens Liesenborghs11, Peter Verhamme1 and Geert Meyfroidt1 Correction to: Trials 21, 981 (2020) https://doi.org/10.1186/s13063-020-04876-0 Following publication of the original article [1], we were notified of a typing mistake in one of the author names. Originally published name: Alexander Schauvlieghe. Corrected name: Alexander Schauwvlieghe. The original article has been corrected. Author details 1 University Hospitals Leuven (UZ Leuven), Leuven, Belgium. 2Catholic University of Leuven (KU Leuven), Leuven, Belgium. 3Universitair Ziekenhuis Gent, Ghent, Belgium. 4Instituut voor Tropische Geneeskunde, Antwerp, The original article can be found online at https://doi.org/10.1186/s13063020-04876-0. * Correspondence: [email protected] † Timothy Devos, Tatjana Geukens and Alexander Schauwvlieghe are co-first authors. 1 University Hospitals Leuven (UZ Leuven), Leuven, Belgium 2 Catholic University of Leuven (KU Leuven), Leuven, Belgium Full list of author information is available at the end of the article
Belgium. 5Sciensano, Elsene, Belgium. 6Rode Kruis Vlaanderen, Mechelen, Belgium. 7Universite Libre de Bruxelles Institut d ‘Immunologie Medicale, Bruxelles, Belgium. 8Universite de Liege, Liege, Belgium. 9Universite Libre de Bruxelles, Bruxelles, Belgium. 10Leuven Coordinating Centre, Leuven, Belgium. 11 Katholieke Universiteit Leuven Rega Institute for Medical Research, Leuven, Belgium. 12Universitair Ziekenhuis Brussel, Bruxelles, Belgium. 13Croix Rouge de Belgique, Bruxelles, Belgium. 14Interuniversity Institute for Biostatistics and statistical Bioinformatics, Leuven, Belgium. 15Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium. 16Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe, Belgium.
Reference 1. Devos, et al. A randomized, multicentre, open-label phase II proof-ofconcept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020;21:981. https://doi.org/10.1186/s13063-020-04876-0.
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any mediu
Data Loading...
